Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -$41.92M, compared with -$63.24M a year earlier.

Context

  • Net debt amounted to 12.0% of total assets at the end of Q1 FY2026, down 2.8 pp from a year earlier.
  • Net debt grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +33.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$41.92M-356.3% QoQ
Last fiscal yearDec 2025
-$9.19M+80.3% YoY
Year agoMar 2025
-$63.24M+33.7% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.7%——
1 year+80.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(9.19M) USD
Year-over-year change
+80.3%

Net Debt vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +33.7% is the 5th highest of 11, against a peer median of +21.6%.
  • Net debt amounts to 12.0% of total assets for LYEL, versus a peer median of 20.2%.
LYEL Competitors
Net Debt for LYEL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALLOAllogene Therapeutics, Inc.Mar 2026$50.74M USD+30.7%-7.0%12.8%
KYTXKyverna Therapeutics, Inc.Mar 2026$1.56M USD+103.1%—0.6%
SLNSilence Therapeutics plcMar 2026-$5.52M USD+91.5%—4.8%
GNLXGenelux CorporationMar 2026-$6.78M USD+53.0%—20.9%
ACIUAC Immune S.A.Mar 2026-CHF 14.87M CHF-0.5%—10.8%
LYELLyell Immunopharma, Inc.Mar 2026-$41.92M USD+33.7%—12.0%
ALDXAldeyra Therapeutics, Inc.Mar 2026-$49.49M USD-42.3%—74.4%
EDITEditas Medicine, Inc.Mar 2026-$51.67M USD+52.0%—34.6%
CABACabaletta Bio, Inc.Mar 2026-$90.19M USD+12.5%—60.9%
AMRNAmarin Corporation plcMar 2026-$125.48M USD-12.5%—19.4%
LRMRLarimar Therapeutics, Inc.Mar 2026-$174.13M USD-970.9%—83.5%
Peer median (excluding LYEL) —+21.6%-7.0%20.2%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents293.83M123.55M145.65M105.6M60.18M
Short-term Investments320.97M516.6M400.58M264.93M187.04M
Net Receivables00000
Inventory00000
Other Current Assets011.14M8.46M9.07M13.72M
Total Current Assets626.29M651.3M554.69M379.59M260.94M
Property, Plant & Equipment (Net)166.64M166.27M142.32M72.94M53.64M
Goodwill00000
Intangible Assets00000
Long-term Investments330.53M115.04M48.51M32.01M19M
Tax Assets00000
Other Non-current Assets3.95M4.96M4.52M6.31M6.47M
Total Non-current Assets501.12M286.27M195.34M111.27M79.11M
Total Assets1.13B937.56M750.03M490.86M340.05M
Account Payables3.21M3.92M4.82M5.37M2.89M
Short-term Debt00000
Tax Payables00000
Deferred Revenue4.99M0002.54M
Other Current Liabilities28.25M22.16M8.8M22.72M13.71M
Total Current Liabilities46.74M37.03M34.52M53.79M49.41M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)79.67M0000
Other Non-current Liabilities4.57M4.11M3.66M3.25M517K
Total Non-current Liabilities150.88M67.28M60.56M54.25M42.44M
Total Liabilities197.62M104.31M95.08M108.04M91.85M
Common Stock24K25K25K29K2K
Retained Earnings(584.36M)(767.48M)(1B)(1.35B)(1.62B)
Accumulated OCI(1.62M)(7.6M)(94K)291K242K
Other Stockholders Equity00000
Minority Interest00000
Total Equity929.79M833.25M654.95M382.82M248.2M
Total Debt67.82M67.7M63.17M58.97M50.99M
Net Debt(226.01M)(55.85M)(82.48M)(46.63M)(9.19M)

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.